ArticleEClinicalMedicine2026

Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial.

Severine Vermeire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.